Fig. 4

NAM supplementation stabilized muscular function of golden retriever muscular dystrophy. A Clinical score assessed monthly in the three treated dogs (n = 3), relative to WT (n = 3), and untreated GRMD dogs (n = 8). B Force production during gait measured by 3D accelerometry: longitudinal follow-up in the three treated dogs during a 3-month-period before treatment (n = 3) and during treatment, relative to age matches WT (n = 3), and untreated GRMD dogs (n = 5 at inclusion, n = 4 from 5 months of age). C Percentage of maximal respiratory and expiratory flows assessed monthly in the three treated dogs (n = 3), relative to WT (n = 3), and untreated GRMD dogs (n = 4). D Percentage of low-flow phase assessed monthly in the three treated dogs (n = 3), relative to WT (n = 3), and untreated GRMD dogs (n = 4)